Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease
Identifieur interne : 000885 ( Istex/Curation ); précédent : 000884; suivant : 000886Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease
Auteurs : Ray L. Watts [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kapil Sethi [États-Unis] ; Matthew Stern [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren Olanow [États-Unis] ; Alex M. Gray [États-Unis] ; Bryan Adams [États-Unis] ; Nancy L. Earl [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-05-15.
English descriptors
Abstract
Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22890
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000885
Links to Exploration step
ISTEX:AE8F7B691828FAC84E10FA533BFBF8E6336E99D6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea></affiliation></author><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Medical College of Georgia, Augusta, Georgia</wicri:regionArea></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai Medical Center, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Gray, Alex M" sort="Gray, Alex M" uniqKey="Gray A" first="Alex M." last="Gray">Alex M. Gray</name><affiliation wicri:level="1"><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Adams, Bryan" sort="Adams, Bryan" uniqKey="Adams B" first="Bryan" last="Adams">Bryan Adams</name><affiliation wicri:level="1"><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name><affiliation wicri:level="1"><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22890</idno><idno type="url">https://api.istex.fr/document/AE8F7B691828FAC84E10FA533BFBF8E6336E99D6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000885</idno><idno type="wicri:Area/Istex/Curation">000885</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea></affiliation></author><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Medical College of Georgia, Augusta, Georgia</wicri:regionArea></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai Medical Center, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Gray, Alex M" sort="Gray, Alex M" uniqKey="Gray A" first="Alex M." last="Gray">Alex M. Gray</name><affiliation wicri:level="1"><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Adams, Bryan" sort="Adams, Bryan" uniqKey="Adams B" first="Bryan" last="Adams">Bryan Adams</name><affiliation wicri:level="1"><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name><affiliation wicri:level="1"><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15">2010-05-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="858">858</biblScope><biblScope unit="page" to="866">866</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</idno><idno type="DOI">10.1002/mds.22890</idno><idno type="ArticleID">MDS22890</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesia</term><term>levodopa</term><term>ropinirole prolonged‐release</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000885 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000885 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:AE8F7B691828FAC84E10FA533BFBF8E6336E99D6
|texte= Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |